199 related articles for article (PubMed ID: 32987493)
1. Bronchial Fistula: Rare Complication of Treatment with Anlotinib.
Deng P; Hu C; Li Y; Cao L; Yang H; Li M; An J; Jiang J; Gu Q
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):858-865. PubMed ID: 32987493
[TBL] [Abstract][Full Text] [Related]
2. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
Li L; Zhang H; Xie Y; Su N; Su S; Zhang X; Cen W
Comput Math Methods Med; 2022; 2022():1475871. PubMed ID: 35251294
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib: First Global Approval.
Syed YY
Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
[TBL] [Abstract][Full Text] [Related]
6. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
7. Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports.
Zhang PL; Liu ZJ
Medicine (Baltimore); 2019 Nov; 98(44):e17700. PubMed ID: 31689797
[TBL] [Abstract][Full Text] [Related]
8. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yu G; Shen Y; Xu X; Zhong F
PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib in treatment of an elderly patient with recurrent advanced SCLC.
Zhang Y; Jia B; Li J; Xu X
Tumori; 2020 Dec; 106(6):NP36-NP40. PubMed ID: 32031060
[TBL] [Abstract][Full Text] [Related]
13. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
15. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
16. [Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):807-816. PubMed ID: 33113621
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
Li S; Niu M; Deng W; Li N; Wei C; Luo S
Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
[Next] [New Search]